C4 Therapeutics Inc (CCCC) Looks Ready for Growth Despite 8.85% Change This Year

C4 Therapeutics Inc (NASDAQ: CCCC) is 8.85% higher on its value in year-to-date trading and has touched a low of $1.06 and a high of $8.42 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CCCC stock was last observed hovering at around $5.62 in the last trading session, with the day’s gains setting it 0.53%.

Currently trading at $6.15, the stock is 3.22% and 26.79% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.51 million and changing 9.43% at the moment leaves the stock 88.46% off its SMA200. CCCC registered 3.54% gain for a year compared to 6-month gain of 79.30%. The firm has a 50-day simple moving average (SMA 50) of $6.51 and a 200-day simple moving average (SMA200) of -$1.02.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a -20.13% loss in the last 1 month and extending the period to 3 months gives it a 232.43%, and is 14.53% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.43% over the week and 9.72% over the month.

Profit margin for the company is -663.05%. Distance from 52-week low is 480.19% and -26.96% from its 52-week high. The company has generated returns on investments over the last 12 months (-47.66%).

C4 Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.68 with sales reaching $3.19M over the same period.The EPS is expected to grow by 0.61% this year, but quarterly earnings will post -30.90% year-over-year. Quarterly sales are estimated to grow 11.80% in year-over-year returns.

C4 Therapeutics Inc (CCCC) Top Institutional Holders

115 institutions hold shares in C4 Therapeutics Inc (CCCC), with institutional investors hold 121.13% of the company’s shares. The shares outstanding are 48.97M, and float is at 38.33M with Short Float at 8.75%. Institutions hold 97.84% of the Float.

The top institutional shareholder in the company is Wasatch Advisors LP with over 7.2 million shares valued at $19.8 million. The investor’s holdings represent 14.64% of the CCCC Shares outstanding. As of Jun 29, 2023, the second largest holder is Price (T.Rowe) Associates Inc with 2.83 million shares valued at $7.78 million to account for 5.75% of the shares outstanding. The other top investors are Soleus Capital Management, L.P. which holds 2.69 million shares representing 5.47% and valued at over $7.4 million, while Millennium Management Llc holds 4.34% of the shares totaling 2.14 million with a market value of $5.87 million.

C4 Therapeutics Inc (CCCC) Insider Activity

A total of 16 insider transactions have happened at C4 Therapeutics Inc (CCCC) in the last six months, with sales accounting for 6 and purchases happening 10 times.

C4 Therapeutics Inc (CCCC): Who are the competitors?

The company’s main competitors (and peers) include AstraZeneca PLC ADR (AZN) that is trading -10.69% down over the past 12 months. AstraZeneca PLC ADR (0A4J) that is -11.04% lower over the same period.